GE completes Orbotech acquisition
GE Healthcare has finalized its acquisition of the assets of Orbotech Medical Solutions, a subsidiary of Orbotech and a manufacturer of cadmium zinc telluride (CZT) detectors used in GE’s Alcyone nuclear medicine technology.
GE said its Alcyone technology combines CZT detectors, focused pin-hole collimation, 3D reconstruction and stationary data acquisition to provide views of cardiac anatomy and functionality.
This acquisition, initially announced in November 2010, follows the recent FDA clearance of the use of CZT technology in assessment and early detection of breast cancer in women at high risk for the disease. GE’s Discovery NM750b Molecular Breast Imaging (MBI) system utilizes a small Field of View CZT gamma camera dedicated to breast imaging. It is intended to improve early detection of breast cancer, especially in women who are less likely to benefit from conventional mammography, as in cases of dense breast where imaging results may be inconclusive, according to GE.
GE said its Alcyone technology combines CZT detectors, focused pin-hole collimation, 3D reconstruction and stationary data acquisition to provide views of cardiac anatomy and functionality.
This acquisition, initially announced in November 2010, follows the recent FDA clearance of the use of CZT technology in assessment and early detection of breast cancer in women at high risk for the disease. GE’s Discovery NM750b Molecular Breast Imaging (MBI) system utilizes a small Field of View CZT gamma camera dedicated to breast imaging. It is intended to improve early detection of breast cancer, especially in women who are less likely to benefit from conventional mammography, as in cases of dense breast where imaging results may be inconclusive, according to GE.